While lower CXCL10 expression is part of our high-risk signature (associated with poor OS and higher T cell exclusion via TIDE), CXCL10 is generally considered a potent chemoattractant for cytotoxic T lymphocytes and NK cells, and its higher expression has often been linked to favorable responses to immunotherapy in melanoma (30, 71). The gene discussed is CXCL10; the disease is melanoma.